New research report on orthopedic biomaterials market in the U.S.

Hyaluronic Acid Market to Almost Double in Size

According to a new global report series by iData Research (www.idataresearch.net), the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for orthopedic biomaterials grew by 11.5% in 2009 and is estimated to reach almost $6.3 billion by 2016. The market for orthopedic hyaluronic acid viscosupplementation (HA) in 2009 increased almost 30% over the previous year due to growth in the market for three-injection-cycle products. The report states that the launch of single-injection-products will stimulate market growth for HA therapies, while the aging population and increased incidence of osteoarthritis will drive the overall market for orthopedic biomaterials.

Orthopedic biomaterials are implanted or applied in or near bone to facilitate healing. This procedure fills in areas where bone tissue is depleted to restore structure and allow for repair, leading to bone augmentation. Some of the fastest-growing market segments include orthopedic stem cells and cartilage repair. In addition, the market for HA is estimated to see significant changes, due to the FDA approval of Genzyme Biosurgery's single-injection product, SynviscOne(R).

"The introduction of single-injection-cycle products in 2009 is attracting new patients to the viscosupplementation market and cannibalizing market shares for existing products," says Dr. Kamran Zamanian, CEO of iData. "Competition is expected to intensify, putting pressure on pricing and influencing procedural volumes."

iData's global series on the Markets for Orthopedic Biomaterials 2010 includes comprehensive analyses of the markets for:

Growth Factor Therapy Bone Graft Substitutes Machined Bone Allografts Hyaluronic Acid Viscosupplementation Resorbable Tissue and Bone Fixation Devices Tendon Allografts Cartilage Repair Platelet and Bone Marrow Concentration Stem Cell Therapy

The report series also includes comprehensive competitive analyses, which cover companies such as Biomet, DePuy, Genzyme, Medtronic, NuVasive, Sanofi Aventis, Smith & Nephew and Synthes, among others.